Skip to content

Scilex Holding Company SCLX Non-cash interest expense

Non-cash interest expense at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.7%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Reported directly by Scilex Holding Company in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's non-cash interest expense?
Scilex Holding Company (SCLX) reported non-cash interest expense of $1.03M in Q1 2026.
What is the long-term trend for Scilex Holding Company's non-cash interest expense?
Over 4 years (2021 to 2025), Scilex Holding Company's non-cash interest expense has grown at a -52.3% compound annual growth rate (CAGR), from $7.91M to $409K.